I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.

Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.

Our increased level of investment in marketing and sales, with the priority on key growth drivers, resulted in a sales growth of 21 percent in Pharmaceuticals in the U.S.,

Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity,

We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.

It's serious from a business perspective, because it impacts the growth and performance of the birds.